HOME / Featured News / NEWS FROM THE FEDS
Ear Candles Under Attack of FDA
Rate This Article:
0
Medpagetoday.com REPORTS HERE that "a federal appeals court has dismissed a lawsuit brought against the FDA by advocates of medical uses for ear candles."

"The U.S. Court of Appeals for the District of Columbia sided with a lower court and ruled Tuesday that the Holistic Candlers and Consumers Association doesn't have the standing to sue the FDA over warning letters the agency sent to makers of the candles in 2010, urging them to stop marketing the candles as treatments for medical conditions."

"Proponents say that ear candles -- long, hollow tubes made of fabric and covered in wax that are inserted into the ear and lit -- create a negative pressure on the ear canal, pulling wax and other debris out. Some suggest that ear candles can treat a variety of other ailments, including ear and sinus infections, and even hearing loss."

"In 2010, the FDA issued an alert about the dangers of ear candles, including inner ear and skin burns, bleeding, eardrum puncture, and delays in patients seeking proper medical treatment. The FDA also issued warning letters to 15 ear candle manufacturers -- three of which are involved in the current lawsuit -- explaining that the companies lacked agency approval to market their products to treat medical conditions and thus it "appeared" they were selling misbranded medical devices."

"Some of the companies targeted by the FDA were marketing the ear candles to treat allergies, headaches, colds, flu, sinus congestion, sore throats, and ear infections, but had not obtained FDA approval to do so. In a letter to one of the companies, the FDA said the company claimed treatment with the candle could relieve vision disorders ... depression, and attention deficit disorder."

The companies suing the FDA deny that the candles are "medical devices" and said they are intended to be used for "relaxation, comfort, reduction of stress, and for the natural furtherance of the well-being of the user."

"The FDA requested that the companies stop marketing, promoting, and distributing ear candles or face potential regulatory action. The ear candle companies sued the FDA claiming a violation of their First Amendment rights and charging that the FDA engaged in "final agency actions" by sending the letters. Under the law, companies can only sue a government agency if the agency's action was "final" and the only way to remedy the situation is to settle the issue in court."

"Lawyers for the FDA argued that the companies lack standing to sue because the letters didn't contain any requirements -- just the suggestion that the companies should stop selling their products -- and thus don't constitute any "final" action or impose any real harm on the companies. Warning letters are the FDA's way of prompting companies to voluntarily agree to comply with the agency."

"The appeals court dismissed the ear candle supporters' charge because the letters don't amount to "final agency action." The FDA said only that the companies "appear" to be intending their ear candles to be used to treat medical conditions, the court stated."

 
Post A Comment
* Indicates Required Field
Comment Title:
* Comments:
Nickname:
* Validation:
Most Recent Comments
 
 
FeaturedNews
Clinical Trial Data Should Be Open for Review
Published 04/30/2012 - 3:14 p.m.  CDT

Original clinical study reports, which contain far more detail than published randomized trials, should be made available to independent researchers seeking to verify efficacy and safety claims.

In support of this argument, the history of the influenza antiviral oseltamivir (Tamiflu), which was approved by the FDA in 1999, was cited. The widespread belief in oseltamivir's efficacy, was based on a meta-analysis of 10 trials conducted by the manufacturer prior to licensure.  But the authors pointed out that the FDA, which was aware of these clinical trials, concluded that oseltamivir had not been shown to reduce complications and required a statement on the drug's label to that effect.  Moreover, oseltamivir was not given an FDA indication for prevention of spread of influenza.

To this, [authors] commented, "If FDA is right, the drug's effectiveness may be no better than aspirin or acetaminophen.'"
...Read More
HR 329 in need of Co Sponsors
Published 04/30/2012 - 11:11 a.m.  CDT

Representative Bob Filner recently introduced the Chiropractic Care to All Veterans Act (H.R. 329). The bill would require the Veterans Administration (VA) to have a chiropractic physician on staff at all major VA medical facilities by 2014. You too can help ensure chiropractic care is available to those who have placed their lives in service to our country. H.R. 329 is in need of cosponsors to assist its likelihood of passage.

CLICK HERE to urge your legislators to cosponsor the bill.
...Read More
Court Sides with Generic-Drug Makers
Published 04/25/2012 - 6:33 a.m.  CDT

In a unanimous decision, the Supreme Court ruled that generic drugmaker Caraco Pharmaceutical Laboratories can sue Novo Nordisk for what Caraco says are exaggerated descriptions of the scope of patents Novo Nordisk holds on a diabetes drug.

A group of Democratic senators has introduced a bill that would allow people to sue generic drugmakers over failing to update their drug labels to include all known risks. The bill is meant to counter last year's Supreme Court decision in a generic drug dispute.
...Read More
Reader Login
Username:
Password:
 Save Login?
Free Sign-up
Forgot Password?
Reader Control Panel

The TCA Web sites will be under going change in the next few weeks.  Please bear with us while we complete some improvements.

Original clinical study reports, which contain far more detail than published randomized trials, should be made available to independent researchers seeking to verify efficacy and safety claims.

In support of this argument, the history of the influenza antiviral oseltamivir (Tamiflu), which was approved by the FDA in 1999, was cited. The widespread belief in oseltamivir's efficacy, was based on a meta-analysis of 10 trials conducted by the manufacturer prior to licensure.  But the authors pointed out that the FDA, which was aware of these clinical trials, concluded that oseltamivir had not been shown to reduce complications and required a statement on the drug's label to that effect.  Moreover, oseltamivir was not given an FDA indication for prevention of spread of influenza.

To this, [authors] commented, "If FDA is right, the drug's effectiveness may be no better than aspirin or acetaminophen.'"

The Kilgore College Small Business Development Center (SBDC) will sponsor an educational seminar for medical office staff, including office managers and billing staff, entitled Basic Workers’ Compensation for Medical Office Staff on Wednesday, May 2, 2012.

Representative Bob Filner recently introduced the Chiropractic Care to All Veterans Act (H.R. 329). The bill would require the Veterans Administration (VA) to have a chiropractic physician on staff at all major VA medical facilities by 2014. You too can help ensure chiropractic care is available to those who have placed their lives in service to our country. H.R. 329 is in need of cosponsors to assist its likelihood of passage.

CLICK HERE to urge your legislators to cosponsor the bill.

An $8 billion Medicare demonstration program is poorly designed and should be cancelled, the nonpartisan Government Accountability Office (GAO) said. The program is designed to reward the highest-quality Medicare Advantage plans, but instead pays out most of its award money to mediocre plans, according to a report.


Ethiopia and Kenya Trips.  Have you ever wanted to provide chiropractic care in another country and give back to those in need?

Dr. Teresa Jones has been volunteering on mission trips to Africa for 4 years and is reaching out to the District 5 for help this year. There are two chances to participate, both in July 2012 and if you are interested please RSVP to frontdesk@wholehealth-care.com to let her know you area interested!


The Patient-Centered Outcomes Research Initiative (PCORI), established by the 2010 Patient Protection and Affordable Care Act, has set five priorities as the group's research agenda for the coming years, with the overall goal of advancing clinical effectiveness research. …. the priorities [are] as follows...

Girls who face multiple social stressors at home as toddlers are more likely to be obese by age 5, researchers found.

Nonpharmacologic pain management appears to be safe for mother and baby, although there is limited published evidence to explain its efficacy, according to a Cochrane Review.

There is more data to support the ef?cacy of pharmacologic pain management, such as epidurals and opioids, but these methods lead to more adverse effects.  This reports reports upon some of these
Regulators on both sides of the Atlantic were slow to inform patients and their doctors about problems with metal-on-metal hip implants and relied on industry officials and consultants in crafting their responses.

Complications included high failure rates and possible systemic effects from elevated metal ion levels in the blood.  An advisory has been issued to surgeons, telling them that patients who have received metal-on-metal implants should have annual checkups for life. The evaluations should include testing for metal ions in the blood as well as for clinical symptoms of device failure.